These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 25518034)

  • 21. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
    Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
    Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
    BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.
    Cheng CT; Tsai CY; Yeh CN; Chiang KC; Chen YY; Wang SY; Chen TW; Tseng JH; Jung SM; Chen TC; Yeh TS
    Anticancer Res; 2014 Nov; 34(11):6617-25. PubMed ID: 25368266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
    Pandey R; Kochar R
    J Gastrointest Cancer; 2012 Dec; 43(4):547-52. PubMed ID: 22847491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.
    Sicklick JK; Lopez NE
    J Gastrointest Surg; 2013 Nov; 17(11):1997-2006. PubMed ID: 23775094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
    Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
    Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy.
    Yu JR; Yang XJ; Yang WL; Gao Y; Zhang Q
    Scand J Gastroenterol; 2007 Sep; 42(9):1138-40. PubMed ID: 17710683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
    Wu PC; Langerman A; Ryan CW; Hart J; Swiger S; Posner MC
    Surgery; 2003 Oct; 134(4):656-65; discussion 665-6. PubMed ID: 14605627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal stromal tumors: diagnosis and treatment.
    Acín-Gándara D; Pereira-Pérez F; Castaño-Pascual A; Durán-Poveda M; Antequera-Pérez A; Miliani-Molina C
    Cir Cir; 2012; 80(1):44-51. PubMed ID: 22472152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).
    Rutkowski P; Nyckowski P; Grzesiakowska U; Nowecki ZI; Nasierowska-Guttmejer A; Pienkowski A; Dudek K; Krawczyk M; Ruka W
    Neoplasma; 2003; 50(6):438-42. PubMed ID: 14689066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative imatinib treatment in patients with advanced gastrointestinal stromal tumors: patient experiences and systematic review of 563 patients.
    Xu J; Ling TL; Wang M; Zhao WY; Cao H
    Int Surg; 2015 May; 100(5):860-9. PubMed ID: 26011207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis.
    Wang J; Yin Y; Shen C; Yin X; Cai Z; Pu L; Fu W; Wang Y; Zhang B
    Medicine (Baltimore); 2020 Feb; 99(9):e19275. PubMed ID: 32118738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
    Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
    Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
    Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor.
    Hou YY; Zhou Y; Lu SH; Qi WD; Xu C; Hou J; Tan YS
    World J Gastroenterol; 2009 Apr; 15(15):1910-3. PubMed ID: 19370794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.
    Cirocchi R; Farinella E; La Mura F; Cavaliere D; Avenia N; Verdecchia GM; Giustozzi G; Noya G; Sciannameo F
    Tumori; 2010; 96(3):392-9. PubMed ID: 20845798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Successful resection of locally advanced gastrointestinal stromal tumor of the ampulla of Vater after treatment with imatinib].
    Park JE; Dong SH; Cho KH; Jang JY; Kim HJ; Kim BH; Chang YW; Chang R
    Korean J Gastroenterol; 2010 Jul; 56(1):39-44. PubMed ID: 20695129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.